These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 30614033)
1. Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. Fan L; Yang Y; Chi C; Ma X; Wang R; Gong Y; Zheng H; Pan J; Zhu Y; Dong B; Xue W Prostate; 2019 May; 79(6):567-573. PubMed ID: 30614033 [TBL] [Abstract][Full Text] [Related]
2. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775 [TBL] [Abstract][Full Text] [Related]
3. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer. Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908 [TBL] [Abstract][Full Text] [Related]
4. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075 [TBL] [Abstract][Full Text] [Related]
5. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060 [TBL] [Abstract][Full Text] [Related]
6. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004 [TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. Fan L; Dong B; Chi C; Wang Y; Gong Y; Sha J; Pan J; Shangguan X; Huang Y; Zhou L; Xue W BMC Urol; 2018 Dec; 18(1):110. PubMed ID: 30509237 [TBL] [Abstract][Full Text] [Related]
8. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Fizazi K; Flaig TW; Stöckle M; Scher HI; de Bono JS; Rathkopf DE; Ryan CJ; Kheoh T; Li J; Todd MB; Griffin TW; Molina A; Ohlmann CH Ann Oncol; 2016 Apr; 27(4):699-705. PubMed ID: 26609008 [TBL] [Abstract][Full Text] [Related]
9. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309 [TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer. Xu N; Zhao J; Zhao F; Liu H; Yin W; Zhu S; Nie L; Sun G; Zheng L; Liu Z; Cai D; Chen J; Dai J; Ni Y; Wang Z; Zhang X; Liang J; Chen Y; Hu X; Pan X; Yin X; Zhu X; Zhang Y; Wang Z; Zeng Y; Wang M; Shen P; Chen N; Zeng H J Cancer Res Clin Oncol; 2023 Aug; 149(10):7247-7258. PubMed ID: 36907910 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659 [TBL] [Abstract][Full Text] [Related]
12. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Rescigno P; Lorente D; Bianchini D; Ferraldeschi R; Kolinsky MP; Sideris S; Zafeiriou Z; Sumanasuriya S; Smith AD; Mehra N; Jayaram A; Perez-Lopez R; Mateo J; Parker C; Dearnaley DP; Tunariu N; Reid A; Attard G; de Bono JS Eur Urol; 2016 Nov; 70(5):724-731. PubMed ID: 26965561 [TBL] [Abstract][Full Text] [Related]
14. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048 [TBL] [Abstract][Full Text] [Related]
16. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. Demirci A; Bilir C; Gülbağcı B; Hacıbekiroğlu İ; Bayoğlu İV; Bilgetekin İ; Koca S; Çınkır HY; Akdeniz N; Gül D; Varım C; Demirci U; Öksüzoğlu B Sci Rep; 2021 Jul; 11(1):14131. PubMed ID: 34239026 [TBL] [Abstract][Full Text] [Related]
17. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Goodman OB; Flaig TW; Molina A; Mulders PF; Fizazi K; Suttmann H; Li J; Kheoh T; de Bono JS; Scher HI Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):34-9. PubMed ID: 24080993 [TBL] [Abstract][Full Text] [Related]
18. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer. Lewis AR; Costello BA; Quevedo F; Pagliaro LC; Sanhueza C; Weinshilboum RM; Kalari KR; Wang L; Kohli M; Tan W; Giridhar KV Prostate; 2023 May; 83(7):649-655. PubMed ID: 36924119 [TBL] [Abstract][Full Text] [Related]
19. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer. von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767 [TBL] [Abstract][Full Text] [Related]
20. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]